Taysha Gene Therapies Announces First Patient Dosed With TSHA-102 In REVEAL Phase 1/2 Trial Under Investigation For Treatment Of Rett Syndrome
Portfolio Pulse from Benzinga Newsdesk
Taysha Gene Therapies has announced the first patient dosed with TSHA-102 in the REVEAL Phase 1/2 trial, a randomized study evaluating the safety and preliminary efficacy of TSHA-102 in adults with Rett syndrome.
June 05, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Taysha Gene Therapies has dosed the first patient with TSHA-102 in the REVEAL Phase 1/2 trial for Rett syndrome treatment.
The announcement of the first patient dosed with TSHA-102 in the REVEAL Phase 1/2 trial is a significant milestone for Taysha Gene Therapies. This news indicates progress in the development of their treatment for Rett syndrome, which could potentially lead to positive results and increased investor interest in the company. As a result, the stock price is likely to go up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100